Business Wire

Alorica and Talkdesk Announce Strategic Partnership to Deploy Next Generation of Customer Experience

17.3.2021 16:30:00 EET | Business Wire | Press release

Share

Alorica, a global leader in customer experience (CX) solutions, and Talkdesk®, Inc., the leading cloud contact center for innovative enterprises, today announced a strategic partnership to deliver turnkey CX solutions. The partnership brings together Talkdesk’s cloud-based contact center platform with Alorica’s award-winning operational execution and best-in-class workforce, providing clients with a complete solution to build customer satisfaction, loyalty and long-term value through a scalable, cost-efficient and secure implementation.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210317005568/en/

“Many businesses are facing the challenge of needing to invest and scale more robust customer service and experience requirements amidst uncertain economic outlooks,” said Greg Haller, chief operating officer, Alorica. “With a deep understanding of the customer and how digital platforms are redefining our industry, Alorica is investing in the right technology and partners that will help our clients navigate their CX transformation successfully. The combined, complementary capabilities of Alorica and Talkdesk give clients a differentiated pathway to cost-effectively elevate the customer experience. Ultimately, this leads to brand loyalty, revenue growth and operational efficiencies.”

Modern consumer expectations have advanced beyond voice-only support to include web, messaging, mobile applications and social platforms as part of the customer journey. In response, service models must deliver fast and easy customer engagement, across all channels, in a way that is both personalized and contextual at every customer touchpoint. However, companies are challenged to activate new technology, high-quality talent and world-class operational models at an accelerated pace while simultaneously reducing risk and improving efficiency.

“Talkdesk is passionate about driving the contact center industry forward with innovative solutions, providing companies with the solutions and flexible consumption-based pricing options they need to set themselves apart from their competition,” said Tiago Paiva, chief executive officer, Talkdesk. “The customer-first philosophy shared by Alorica and Talkdesk helps enterprises around the world build brand trust and loyalty by delivering exceptional customer interactions.”

Alorica and Talkdesk are joining forces to achieve these goals, enabling a more comprehensive understanding of client needs and the ability to quickly provide tailored offerings. Through their combined capabilities, clients will benefit from an integrated operating model for hiring, training, analytics, knowledge management, quality assurance, call routing and automation. Talkdesk’s native cloud platform complements Alorica’s embedded systems and empowers a skilled workforce, giving clients an industry-leading and strategic executional partner to efficiently establish and scale the latest CX solutions through a single interface at a fraction of the cost of building standalone operations.

By leveraging Talkdesk CX Cloud™, Alorica further enhances its enterprise performance at scale on behalf of clients around the world, resulting in increased productivity, customer satisfaction and cost savings. Through this one-of-a-kind partnership, Alorica and Talkdesk are setting a new benchmark for the contact center solutions market with scalability, security and reliability. This is backed not only by Talkdesk’s 100% uptime Service Level Agreement, but also implemented through one of the largest customer experience providers in the world—Alorica.

Additional Resources:

Tweet this : Ready for the next generation of #CX? @OfficialAlorica and @Talkdesk are excited to announce a new strategic partnership as an integrated solution to help brands deploy global omnichannel experiences tailored to their business

Social Networks:

About Alorica

We are made up of 100,000 passionate problem solvers who make lives better through positive customer interactions—at every touchpoint—across voice, chat and social. Leveraging innovative technologies—including intelligent automation and a comprehensive analytics suite—we support the world’s most respected brands with the best talent and resources necessary to create insanely great experiences. Alorica provides a host of world-class services—from customer care to financial solutions and digital services—to clients across industries of all kinds, many of whom are on the Fortune 500. Alorica contact centers and operation hubs span the globe with locations in 14 countries. To learn more, visit www.Alorica.com.

About Talkdesk

Talkdesk® is the cloud contact center for innovative enterprises. Combining enterprise performance with consumer simplicity, Talkdesk easily adapts to the evolving needs of support and sales teams and their end-customers, resulting in higher customer satisfaction, productivity and cost savings. Over 1,800 innovative companies around the world, including IBM, Acxiom, 2U, Trivago and YMCA rely on Talkdesk to make customer experience their competitive advantage. Learn more and request a demo at www.talkdesk.com.

Talkdesk is a registered trademark of Talkdesk, Inc. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Alorica
Sunny Yu
sunny.yu@alorica.com
(714) 469-8385

Talkdesk
Christie Blake
christie.blake@talkdesk.com
(781) 405-3616

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye